Investment Rating - The investment rating for China Resources Sanjiu (华润三九) is "Buy" (maintained) [1][6] Core Views - The company reported a revenue of 27.617 billion yuan for 2024, representing a year-on-year growth of 11.63%, and a net profit attributable to shareholders of 3.368 billion yuan, up 18.05% year-on-year [3] - The CHC (Consumer Health Care) business maintained its leading position with a revenue of 12.482 billion yuan in 2024, growing 14.13% year-on-year, while the prescription drug segment achieved a revenue of 6.006 billion yuan, up 15.04% year-on-year [3] - The company is expected to continue its steady growth, with projected revenues of 30.986 billion yuan, 34.549 billion yuan, and 38.004 billion yuan for 2025, 2026, and 2027 respectively, reflecting a growth rate of 12%, 12%, and 10% [1][3] Summary by Relevant Sections Financial Performance - For 2023, the company achieved a revenue of 24.739 billion yuan and a net profit of 2.853 billion yuan, with respective growth rates of 37% and 17% [1] - The projected earnings per share (EPS) for 2025 is 2.98 yuan, with a net profit forecast of 3.821 billion yuan [1][4] Business Segments - The CHC business segment is focusing on enhancing its product mix, particularly in cold, skin, and gastrointestinal categories, while the prescription drug segment is seeing a recovery in its formula granule business [3] - The company is also advancing its merger with Kunming Pharmaceutical Group and the acquisition of Tianjin Tasly Pharmaceutical, which is expected to enhance its competitive edge in the traditional Chinese medicine sector [3] Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 19.0 in 2023 to 14.1 in 2025, indicating an improving valuation as earnings grow [1][4] - The price-to-book (P/B) ratio is expected to decline from 2.9 in 2023 to 2.3 in 2025, reflecting a strengthening financial position [1][4]

证券代码：000999 证券简称：华润三九 公告编号：2025-024 二、参加人员 公司董事长邱华伟先生，董事、总裁吴文多先生，董事、副总裁周辉女士，副总裁 王亮先生，财务总监、董事会秘书邢健先生以及公司独立董事将出席公司 2024 年度业 绩说明会（如有特殊情况，参会人员将可能调整）。 三、投资者参加方式 1. 投资者可于 2025 年 3 月 24 日（星期一）下午 15:30-16:30，登录全景路演 （https://rs.p5w.net）参加公司 2024 年度业绩说明会。 华润三九医药股份有限公司 关于举行 2024 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司(以下简称"公司")于 2025 年 3 月 13 日发布公司 2024 年年度报告，为便于投资者了解公司 2024 年度生产经营情况及未来发展规划，公司将 于 2025 年 3 月 24 日（星期一）下午 15:30-16:30 举办 2024 年度业绩说明会。 一、业绩说明会召开的时间、地点 四、联系方式 联系部门：证券事务部 联系电话 ...

Summary of the Conference Call for China Resources Sanjiu (华润三九) Company Overview - **Company Name**: China Resources Sanjiu - **Industry**: Pharmaceuticals - **Business Segments**: - Health Consumer Products (CHC) - Prescription Drugs Key Financial Performance - **2024 Revenue**: RMB 27.62 billion, up 12% year-on-year [1] - **Net Profit**: RMB 3.37 billion, up 18% year-on-year [1] - **Q4 2024 Revenue**: RMB 7.88 billion, up 29% year-on-year [1] - **Q4 2024 Net Profit**: RMB 410 million, down 9% year-on-year [1] - **Cash Dividend**: RMB 1.32 per share, with a payout ratio of 50.34% [1] Segment Performance - **Health Consumer Products Revenue**: RMB 12.48 billion, up 14% [2] - **Prescription Drugs Revenue**: RMB 6.01 billion, up 15% [2] - **Traditional Chinese Medicine Revenue**: RMB 5.21 billion, up 7.3% [2] - **Gross Margin**: 51.9%, down 1.4 percentage points year-on-year, primarily due to a decline in prescription drug margins [2] - **CHC Gross Margin**: Increased by 0.3 percentage points to 60.9% [2] - **Prescription Drug Gross Margin**: Decreased by 4.6 percentage points to 47.5% [2] - **Expense Ratio**: Decreased by 2.1 percentage points to 35%, with sales and management expense ratios at 26% and 8.9% respectively [2] Future Outlook - **2025 Revenue and Profit Guidance**: Expected to maintain double-digit growth [3] - **CHC Business**: Anticipated to solidify its leading position with new product launches [3] - **Prescription Drug Strategy**: Focus on both existing areas and new opportunities post-merger with Tianjin Tasly [3] - **Gross Margin Expectations**: CHC margins expected to remain stable, while prescription drug margins may improve with a higher proportion of innovative products [3] - **Sales Expense Ratio**: Expected to remain stable, with potential improvements for Tianjin Tasly [3] Valuation and Investment Rating - **Target Price**: Increased from RMB 58.90 to RMB 61.00, maintaining a "Buy" rating [4] - **EPS Forecast Adjustments**: 2025-2027 EPS estimates reduced by 8%, 11%, and 15% respectively [4] - **Market Capitalization**: RMB 53.8 billion (approximately USD 7.44 billion) [5] - **Current Share Price**: RMB 41.90 [5] Important Metrics - **12-Month Rating**: Buy [5] - **52-Week Price Range**: RMB 51.82 - 36.41 [5] - **Average Daily Trading Volume**: 8,369 thousand shares [5] - **Projected Stock Price Increase**: 45.6% [9] - **Projected Dividend Yield**: 3.6% [9] - **Projected Total Return**: 49.2% [9] Risks and Challenges - **Policy Risks**: Potential delays in policy implementation affecting market share in traditional Chinese medicine [11] - **Healthcare Cost Control**: Pressure on sales growth for certain prescription drugs due to healthcare cost controls [11] - **Self-Medication Price Increases**: Risk of volume declines due to price increases in self-medication products [11] - **M&A Integration Risks**: Challenges in the integration process with Tianjin Tasly [11] Analyst Information - **Analysts**: - Zhu Yifan - Chen Zhenbo, PhD - Liu Jiazhuo [6] This summary encapsulates the key points from the conference call regarding China Resources Sanjiu, highlighting its financial performance, future outlook, valuation, and associated risks.

Investment Rating - The report maintains an investment rating of Buy-A for the company [5]. Core Views - The company achieved a revenue of 27.617 billion yuan in 2024, representing a year-on-year growth of 11.63%, and a net profit of 3.368 billion yuan, up 18.05% year-on-year [1][2]. - The core business, Consumer Health Care (CHC), showed robust growth with a revenue of 12.482 billion yuan, increasing by 14.13% year-on-year, solidifying the company's position in the self-medication sector [3][10]. - The strategic acquisition of a 28% stake in Tian Shi Li is expected to enhance synergies in innovation, manufacturing, and marketing, thereby strengthening the company's competitive edge in the industry [11]. Financial Performance - In Q4, the company reported a revenue of 7.876 billion yuan, a year-on-year increase of 28.47%, but a net profit decline of 9.39% [1]. - The gross profit margin for 2024 was 51.86%, a decrease of 1.39 percentage points, while the net profit margin improved slightly to 13.68%, an increase of 0.85 percentage points [2]. - The company anticipates revenue growth rates of 10.3%, 10.4%, and 10.5% for 2025 to 2027, with net profit growth rates of 13.5%, 14.5%, and 14.6% respectively [11][13]. Business Segments - The prescription drug segment generated a revenue of 6.006 billion yuan in 2024, reflecting a year-on-year growth of 15.04%, driven by enhanced medical leadership and product commercialization [4][10]. - The traditional Chinese medicine segment achieved a revenue of 5.213 billion yuan, up 7.33% year-on-year, while the pharmaceutical commercial segment reported a revenue of 3.373 billion yuan, a 2.06% increase [10]. Market Position and Strategy - The company has successfully launched several new products in the self-medication category, including 999 Ice Lianqing Throat Spray and 999 Yipingfeng Oral Liquid, contributing to its market leadership [3][10]. - The integration with Kunming Pharmaceutical Group is progressing steadily, focusing on brand recognition and market positioning for their products [10]. Valuation - The six-month target price for the company is set at 53.57 yuan, which corresponds to an 18 times dynamic price-to-earnings ratio for 2025 [11].

Investment Rating - The report maintains a "Buy" rating for the company [2][4]. Core Views - The company's performance met expectations, with a projected steady growth for 2025. In 2024, the company achieved a revenue of 27.617 billion yuan, a year-on-year increase of 11.6%, and a net profit attributable to the parent company of 3.368 billion yuan, up 18.1% year-on-year. The company anticipates double-digit growth in revenue and matching net profit growth for 2025 [7][8]. - The Consumer Health Care (CHC) segment showed rapid growth, generating revenue of 12.48 billion yuan, a 14.1% increase, while the prescription drug segment also saw a recovery with a revenue of 6 billion yuan, up 15.0%. Traditional Chinese medicine (Kunming Pharmaceutical) generated 5.2 billion yuan, a 7.3% increase [7][8]. - The company reduced its sales expense ratio, leading to improved profitability. The gross margin for 2024 was 51.9%, a decrease of 1.3 percentage points year-on-year, while the net profit margin reached 13.7%, an increase of 0.9 percentage points year-on-year [7][8]. Financial Summary - The company’s projected financials for 2025 include: - Revenue: 30.299 billion yuan, a 9.7% increase from 2024 - Operating profit: 5.076 billion yuan, a 13.4% increase - Net profit attributable to the parent company: 3.841 billion yuan, a 14.0% increase - Earnings per share: 2.99 yuan [5][8]. - The company’s financial ratios for 2023A to 2027E indicate a stable growth trajectory, with net profit margins expected to rise from 11.5% in 2023 to 13.7% in 2027 [5][8].

核心观点 盈利预测与投资建议 ⚫ 我们维持盈利预期，预测公司 2025-2027 年每股收益分别为 2.99、3.39、3.93 元， 参考可比公司平均市盈率，我们维持 2025 年 19 倍 PE 估值，维持目标价 56.81 元， 维持"买入"评级。 风险提示 ⚫ 市场竞争加剧风险；兼并整合风险；政策监管风险；原材料价格风险；商誉减值风 险等。 华润三九 000999.SZ 公司研究 | 年报点评 业绩符合预期，核心业务稳健增长 | | 买入 （维持） | | --- | --- | | 股价（2025年03月14日） | 41.9 元 | | 目标价格 | 56.81 元 | | 52 周最高价/最低价 | 51.41/35.45 元 | | 总股本/流通 A 股（万股） | 128,430/127,565 | | A 股市值（百万元） | 53,812 | | 国家/地区 | 中国 | | 行业 | 医药生物 | | 报告发布日期 | 2025 年 03 月 17 日 | | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对 ...

上海市锦天城（深圳）律师事务所 关于 华润三九医药股份有限公司 重大资产购买 之 补充法律意见书（一） 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 | | 声明事项 | 4 | | --- | --- | --- | | 正 | 文 | 6 | | 一、 | 《问询函》问题 8 | 6 | 上海市锦天城（深圳）律师事务所 补充法律意见书（一） 上海市锦天城（深圳）律师事务所 关于华润三九医药股份有限公司 重大资产购买之 补充法律意见书（一） 致：华润三九医药股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受华润三九医药 股份有限公司（以下简称"上市公司/华润三九"）的委托，并根据上市公司与 本所签订的《专项法律服务合同》，作为上市公司本次重大资产重组的专项法律 顾问。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司重大 资产重组管理办法》《上市公司证券发行注册管理办法》《上市公司监管指引第 9 号——上市公司筹划和实施重大资产重组的监管要求》等有关法律、法规以及 中国证券监督管理委员 ...

目 录 | 关于开发支出……………………………………………………第 一、 | 1—8 | 页 | | --- | --- | --- | | 二、关于销售费用………………………………………………… 第 | 8—13 | 页 | | 三、关于应收账款与应收款项融资及存货………………………第 | 13—22 | 页 | 问询函专项说明 天健函〔2025〕127 号 深圳证券交易所： 由华润三九医药股份有限公司（以下简称华润三九公司或公司）转来的《关 于对华润三九医药股份有限公司重大资产购买的问询函》（并购重组问询函〔2025〕 第 2 号，以下简称问询函）奉悉。我们已对问询函中需要我们说明的财务事项进 行了审慎核查，现汇报说明如下。 一、报告书显示，截至 2024 年末，标的公司开发支出账面价值为 14.46 亿 元。2024 年，标的公司针对本期已暂停、未来研发进展存在重大不确定性的研 发项目计提开发支出减值准备 1.93 亿元。请你公司： （1）说明标的公司报告期内研发投入具体项目、开发支出核算内容、研发 费用资本化金额，并结合研发计划、研发进展、同行业可比公司会计政策等，说 明报告期内研发投入资本化的会计处 ...

华泰联合证券有限责任公司 关于 华润三九医药股份有限公司 重大资产购买 之 独立财务顾问报告 （修订稿） 二〇二五年三月 华润三九医药股份有限公司重大资产购买 独立财务顾问报告（修订稿） 声明与承诺 华泰联合证券有限责任公司（以下简称"华泰联合"、"本独立财务顾问"） 接受华润三九医药股份有限公司（以下简称"华润三九"、"上市公司"或"公 司"）的委托，担任其重大资产购买的独立财务顾问，就该事项向上市公司全体 股东提供独立意见，并制作本独立财务顾问报告。 本独立财务顾问报告是依据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业 务管理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市 公司重大资产重组申请文件》《上市公司监管指引第 9 号——上市公司筹划和 实施重大资产重组的监管要求》和《深圳证券交易所上市公司重大资产重组审 核规则》等相关法律法规的规定和要求，以及证券行业公认的业务标准、道德 规范，经过审慎调查，本着诚实信用和勤勉尽责的态度，就本次交易认真履行 尽职调查义务，对上市公司相关的申报和披露文件进行审慎核查后出具的，旨 ...

一、本次交易的内幕信息知情人自查期间 华泰联合证券有限责任公司 关于华润三九医药股份有限公司 本次交易相关主体买卖股票情况的自查报告的核查意见 华润三九医药股份有限公司（以下简称"华润三九"、"上市公司"）拟以支付现 金的方式向天士力生物医药产业集团有限公司（以下简称"天士力集团"）及其一致行 动人天津和悦科技发展合伙企业（有限合伙）（以下简称"天津和悦"）、天津康顺科 技发展合伙企业（有限合伙）（以下简称"天津康顺"）、天津顺祺科技发展合伙企业 （有限合伙）（以下简称"天津顺祺"）、天津善臻科技发展合伙企业（有限合伙）（以 下简称"天津善臻"）、天津通明科技发展合伙企业（有限合伙）（以下简称"天津通 明"）、天津鸿勋科技发展合伙企业（有限合伙）（以下简称"天津鸿勋"）合计购买 其所持有的天士力医药集团股份有限公司（以下简称"天士力"、"标的公司"）418,306,002 股股份（占天士力已发行股份总数的 28%）（以下简称"本次交易"）。此外，天士力 集团同意，天士力集团应出具书面承诺，承诺在登记日后放弃其所持有的天士力 5%股 份所对应的表决权等方式，使其控制的表决权比例不超过 12.5008%。本次交易 ...